3.31 USD
▼-0.14-4.06%
盘后 3.41 0.00%
2026-11-20
市值
$218.90M
市盈率
—
EPS
-1.03
股息率
—
52 周区间
3.31 – 8.48
成交量
681.75K
Beta
0.46
目标价
17.00
52W 低 3.3152W 高 8.48
价格走势
公司简介
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinica...